newsfilter
← Latest News
GlobeNewswire·

Cancer Research UK Dose First Patient in Phase I/IIa Trial of Lung Cancer Immunotherapy Vaccine

OXFORD, United Kingdom, Jan. 18, 2022 (GLOBE NEWSWIRE) -- Cancer Research UK, Vaccitech plc (NASDAQ:VACC) and the Ludwig Institute for Cancer Research (Ludwig), today announce the first patient dosed in the MAGE trial, which is testing a novel immunoth